CorMedix (CRMD) shares were up over 11% in Thursday trading following its Q2 results and guidance.
Earlier, the company reported a Q2 earnings of $0.29 per diluted share, up from $0.28 a year earlier.
Revenue for the three months ended June 30 was $101.9 million, up from $39.7 million a year earlier.
Analysts polled by FactSet expected $97.4 million.
For 2026, the company kept its revenue guidance of $325 million to $345 million, while raising its adjusted EBITDA guidance to a range of $125 million to $140 million.
Analysts expected $335.3 million for revenue.
Price: $7.95, Change: $+0.85, Percent Change: +11.90%